| Definitions and statistical properties of master protocols for personalized medicine in oncology |
10 |
| The stratified win ratio |
8 |
| Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data |
7 |
| A comparison of multiple imputation methods for incomplete longitudinal binary data |
5 |
| Methods for the analysis of multiple endpoints in small populations: A review |
5 |
| New designs for basket clinical trials in oncology |
5 |
| Statistical Methods for Conditional Survival Analysis |
4 |
| Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients |
4 |
| Optimal threshold selection methods under tree or umbrella ordering |
4 |
| Personalized Risk Prediction in Clinical Oncology Research: Applications and Practical Issues Using Survival Trees and Random Forests |
4 |
| Multiplicity issues in exploratory subgroup analysis |
4 |
| Advances in p-Value Based Multiple Test Procedures |
4 |
| Regulatory issues with multiplicity in drug approval: Principles and controversies in a changing landscape |
3 |
| Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect |
3 |
| Biomarker threshold adaptive designs for survival endpoints |
3 |
| On Enrichment Strategies for Biomarker Stratified Clinical Trials |
3 |
| Assay sensitivity in Hybrid thorough QT/QTc (TQT) study |
3 |
| Estimation of delay time in survival data with delayed treatment effect |
3 |
| Sample size for comparing negative binomial rates in noninferiority and equivalence trials with unequal follow-up times |
3 |
| Estimating the subgroup and testing for treatment effect in a post-hoc analysis of aclinical trial with a biomarker |
2 |
| Algorithms for imputing partially observed recurrent events with applications to multiple imputation in pattern mixture models |
2 |
| A Bayesian adaptive design for cancer phase I trials using a flexible range of doses |
2 |
| Randomized dose-escalation designs for drug combination cancer trials with immunotherapy |
2 |
| One-tailed asymptotic inferences for the difference of proportions: Analysis of 97 methods of inference |
2 |
| A fast and reliable test for parallelism in bioassay |
2 |
| Asymptotic confidence interval construction for proportion ratio based on correlated paired data |
2 |
| Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies |
2 |
| A decision theoretical modeling for Phase III investments and drug licensing |
2 |
| Probability monitoring procedures for sample size determination |
2 |
| Applying CHW method to 2-in-1 design: gain or lose? |
2 |
| Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methods |
2 |
| Profile clustering in clinical trials with longitudinal and functional data methods |
2 |
| Power calculation in stepped-wedge cluster randomized trial with reduced intervention sustainability effect |
2 |
| Robust outcome weighted learning for optimal individualized treatment rules |
1 |
| Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies |
1 |
| Good statistical practice in utilizing real-world data in a comparative study for premarket evaluation of medical devices |
1 |
| Studying treatment-effect heterogeneity in precision medicine through induced subgroups |
1 |
| Estimation on conditional restricted mean survival time with counting process |
1 |
| Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints |
1 |
| An enhanced mixture method for constructing gatekeeping procedures in clinical trials |
1 |
| Multiple comparisons in non-inferiority trials: Reaction to recent regulatory guidance on multiple endpoints in clinical trials |
1 |
| Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review |
1 |
| Adaptive clinical endpoint bioequivalence studies with sample size re-estimation based on a nuisance parameter |
1 |
| Influence Analysis for the Area Under the Receiver Operating Characteristic Curve |
1 |
| Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework |
1 |
| Randomization-based analysis of covariance for inference in the sequential parallel comparison design |
1 |
| Combination of the weighted kappa coefficients of two binary diagnostic tests |
1 |
| Evaluation of Alzheimer's disease progression based on clinical dementia rating scale with missing responses and covariates |
1 |
| Curtailed two-stage design for comparing two arms in randomized phase II clinical trials |
1 |
| Interchangeability Of Biological Drug Products-FDA Draft Guidance |
1 |
